References
- Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. Rockville, MD: Center for Behavioral Health Statistics and Quality; 2017.
- National Institute on Drug Abuse. Overdose Death Rates. National Institute on Drug Abuse. https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates. Published August 9, 2018. Accessed October 8, 2018.
- Centers for Disease Control and Prevention. Identifying increases in opioid overdoses. Centers for Disease Control and Prevention. https://www.cdc.gov/vitalsigns/opioid-overdoses/index.html. Published March 16, 2018. Accessed July 4, 2018.
- Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–2066.
- Comer SD, Collins ED. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther. 2002;303(2):695–703.
- Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8(5):315–326.
- Schwartz RP, Gryczynski J, O’Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Health. 2013;103(5):917–922.
- Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
- Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review. Curr Drug Abuse Rev. 2011;4(1):28–41.
- Substance Abuse and Mental Health Services Administration. Buprenorphine Waiver Management. Substance Use and Mental Health Services Administration. https://www.samhsa.gov/programs-campaigns/medication-assisted-treatment/training-materials-resources/buprenorphine-waiver. Published June 22, 2015. Accessed July 4, 2018.
- Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–e63.
- Crawford C. Overcoming barriers to opioid treatment takes center stage. Am Acad Fam Phys. https://www.aafp.org/news/health-of-the-public/20170811opioidsstudy.html
- DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health. 2015;15:3019.
- Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1393–1398.
- Sontag D. Addiction treatment with a dark side. The New York Times 2018; https://www.nytimes.com/2013/11/17/health/in-demand-in-clinics-and-on-the-street-bupe-can-be-savior-or-menace.html. Published November 16, 2013. Accessed July 13,
- Macy B. Addicted to a treatment for addiction. The New York Times 2018; https://www.nytimes.com/2016/05/29/opinion/sunday/addicted-to-a-treatment-for-addiction.html. Published January 19, 2018. Accessed July 13.
- Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther. 1995;274(1):361–372.
- Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569–580.
- Bliley T. Drug Addiction Treatment Act of 2000. 2000. https://www.congress.gov/bill/106th-congress/house-bill/2634. Accessed July 4, 2018.
- Clark RE, Baxter JD. Responses of state Medicaid programs to buprenorphine diversion: Doing more harm than good? Jama Intern Med. 2013;173(17):1571–1572.
- American Society of Addiction Medicine. Implications for opioid addiction treatment. American Society of Addiction Medicine; 2013.
- Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1–7.
- Bronson J, Stroop J, Zimmer S, Berzofsky M. Drug use, dependence, and abuse among state prisoners and jail inmates, 2007-2009. United States Department of Justice; 2017.
- Alex B, Weiss DB, Kaba F, et al. Death after jail release: Matching to improve. J Correct Health Care. 2017;23(1):83–87.
- Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592–600.
- Binswanger IA, Stern MF, Deyo RA, et al. Release from prison—A high risk of death for former inmates. N Engl J Med. 2007;356(2):157–165.
- Merrall ELC, Kariminia A, Binswanger IA, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010;105(9):1545–1554.
- Friedmann PD, Hoskinson R, Gordon M, et al. Medication-assisted treatment in criminal justice agencies affiliated with the Criminal Justice-Drug Abuse Treatment Studies (CJ-DATS): Availability, barriers & intentions. Subst Abuse. 2012;33(1):9–18.
- Vestal C. At Rikers Island, a legacy of Medication-Assisted Opioid Treatment. Pew Charitable Trusts. http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2016/05/23/at-rikers-island-a-legacy-of-medication-assisted-opioid-treatment. Published May 23, 2016. Accessed May 23, 2016.
- Krawczyk N, Picher CE, Feder KA, Saloner B. Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Aff Millwood. 2017;36(12):2046–2053.
- Deehan M. Sheriff warns that new white house drug policy could be boon to prison suboxone smuggling. WGBH 2018; https://www.wgbh.org/news/post/sheriff-warns-new-white-house-drug-policy-could-be-boon-prison-suboxone-smuggling. Published November 9, 2015. Accessed July 4.
- Kilmer M. Maryland’s smart move to stop a smuggling problem in prison. Washington Post. 2018; https://www.washingtonpost.com/opinions/smuggling-of-opioid-recovery-drug-furthers-addictions/2017/02/24/7fc42598-efdf-11e6-9973-c5efb7ccfb0d_story.html. Published February 24, 2017. Accessed July 4.
- Nunn A, Zaller N, Dickman S, et al. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105(1–2):83–88.
- Schwartzapfel B. A better way to treat addiction in jail. The Marshall Project 2018; https://www.themarshallproject.org/2017/03/01/a-better-way-to-treat-addiction-in-jail. Published March 2, 2017. Accessed July 4.
- Matusow H, Dickman SL, Rich JD, et al. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44(5):473–480.
- Belenko S, Hiller M, Hamilton L. Treating substance use disorders in the criminal justice system. Curr Psychiatry Rep. 2013;15(11).
- Green TC, Clarke J, Brinkley-Rubinstein L, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. J Am Med Assoc. 2018;75(4):405–407.
- Office of National Drug Control Policy. Convening: medication assisted treatment for justice-involved populations. Washington, DC: Office of National Drug Control Policy; 2016.
- Pecoraro A, Woody GE. Medication-assisted treatment for opioid dependence: making a difference in prisons. F1000 Med Rep. 2011;3:1.
- Tomasino V, Swanson AJ, Nolan J, Shuman HI. The Key Extended Entry Program (KEEP): A methadone treatment program for opiate-dependent inmates. Mt Sinai J Med. 2001;68(1):14–20.
- Allen B, Harocopos A. Non-prescribed buprenorphine in New York City: Motivations for use, practices of diversion, and experiences of stigma. J Subst Abuse Treat. 2016;70:81–86.
- Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. Factors contributing to the rise of buprenorphine misuse: 2008-2013. Drug Alcohol Depend. 2014;142:98–104.
- Bazazi AR, Yokell M, Fu JJ, Rich JD, Zaller ND. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med. 2011;5(3):175–180.
- Genberg BL, Gillespie M, Schuster CR, et al. Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland. Addict Behav. 2013;38(12):2868–2873.
- Kenney SR, Anderson BJ, Bailey GL, Stein MD. The relationship between diversion-related attitudes and sharing and selling buprenorphine. J Subst Abuse Treat. 2017;78:43–47.
- Gwin Mitchell S, Kelly SM, Brown BS, et al. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict. 2009;18(5):346–355.
- Schuman-Olivier Z, Albanese M, Nelson SE, et al. Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers. J Subst Abuse Treat. 2010;39(1):41–50.
- Fox AD, Chamberlain A, Sohler NL, Frost T, Cunningham CO. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. J Subst Abuse Treat. 2015;48(1):112–116.
- Cunningham CO, Roose RJ, Starrels JL, et al. Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes. J Addict Med. 2013;7(4):287–293.
- Whitley SD, Sohler NL, Kunins HV, et al. Factors associated with complicated buprenorphine inductions. J Subst Abuse Treat. 2010;39(1):51–57.
- Monico LB, Mitchell SG, Gryczynski J, et al. Prior experience with non-prescribed buprenorphine: Role in treatment entry and retention. J Subst Abuse Treat. 2015;57:57–62.
- Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425–431.
- Center for Behavioral Health Statistics and Quality. Emergency department visits involving buprenorphine. Rockville, MD: Substance Use and Mental Health Services Administration; 2013.
- Paone D, Tuazon E, Stajic M, et al. Buprenorphine infrequently found in fatal overdose in New York City. Drug Alcohol Depend. 2015;155:298–301.
- Dasgupta N, Bailey EJ, Cicero T, et al. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med. 2010;11(7):1078–1091.
- Lee S, Klein-Schwartz W, Welsh C, Doyon S. Medical outcomes associated with nonmedical use of methadone and buprenorphine. J Emerg Med. 2013;45(2):199–205.
- Yang A, Arfken CL, Johanson C-E. Steps physicians report taking to reduce diversion of buprenorphine. Am J Addict. 2013;22(3):184–187.
- Li X, Shorter D, Kosten TR. Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies. Expert Opin Pharmacother. 2014;15(15):2263–2275.
- Richert T, Johnson B. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden. Harm Reduct J. 2015;12:1.
- Cicero TJ, Surratt HL, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag. 2007;3(6):302–308.
- Lofwall MR, Havens JR. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. Drug Alcohol Depend. 2012;126(3):379–383.
- Kourounis G, Richards BDW, Kyprianou E, et al. Opioid substitution therapy: Lowering the treatment thresholds. Drug Alcohol Depend. 2016;161:1–8.
- Bramson H, Des Jarlais DC, Arasteh K, et al. State laws, syringe exchange, and HIV among persons who inject drugs in the United States: History and effectiveness. J Public Health Pol. 2015;36(2):212–230.
- Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J Addict Dis. 2006;25(3):89–96.
- Song Z, Hill C, Bennet J, Vavasis A, Oriol NE. Mobile clinic in Massachusetts associated with cost savings from lowering blood pressure and emergency department use. Health Aff Millwood. 2013;32(1):36–44.
- Greenfield L, Brady JV, Besteman KJ, De Smet A. Patient retention in mobile and fixed-site methadone maintenance treatment. Drug Alcohol Depend. 1996;42(2):125–131.
- Hall G, Neighbors CJ, Iheoma J, et al. Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals. J Subst Abuse Treat. 2014;46(4):511–515.
- Sullivan LE, Bruce RD, Haltiwanger D, et al. Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis. 2006;43(Supplement_4):S191–S196.
- Patrick SW, Fry CE, Jones TF, Buntin MB. Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Aff Millwood. 2016;35(7):1324–1332.
- Lin LA, Lofwall MR, Walsh SL, Gordon AJ, Knudsen HK. Perceptions and practices addressing diversion among US buprenorphine prescribers. Drug Alcohol Depend. 2018;186:147–153.
- Lofwall MR, Wunsch MJ, Nuzzo PA, Walsh SL. Efficacy of continuing medical education to reduce the risk of buprenorphine diversion. J Subst Abuse Treat. 2011;41(3):321–329.
- American Society of Addiction Medicine. Nurse practitioners and physician assistants prescribing buprenorphine. American Society of Addiction Medicine. https://www.asam.org/resources/practice-resources/nurse-practitioners-and-physician-assistants-prescribing-buprenorphine. Published 2018. Accessed August 30, 2018.
- Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a dea waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. J Rural Health. 2019;35(1):108–112.
- Andrilla CHA, Patterson DG, Moore TE, Coulthard C, Larson EH. Projected contributions of nurse practitioners and physicians assistants to buprenorphine treatment services for opioid use disorder in rural areas. Med Care Res Rev. 2018:1077558718793070. August
- Williams T. Opioid users are filling jails. why don’t jails treat them? The New York Times 2018; https://www.nytimes.com/2017/08/04/us/heroin-addiction-jails-methadone-suboxone-treatment.html. Published August 4, 2017. Accessed July 4,